10 Best Australian Stocks to Buy Now

8. Mesoblast Limited (NASDAQ:MESO)

Number of Hedge Fund Holdings: 3

Mesoblast Limited (NASDAQ:MESO) is a leading biotechnology company specializing in the development and commercialization of cell therapies for serious and life-threatening inflammatory and degenerative diseases. The company’s flagship product, Remestemcel-L (Ryoncil), recently received FDA approval for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients aged two months and older.

With the FDA approval of Remestemcel-L, Mesoblast Limited (NASDAQ:MESO) is poised to enter a critical phase of commercialization. The company has been actively preparing for this launch by hiring a dedicated commercial team, engaging with key opinion leaders in the medical community, and establishing relationships with bone marrow transplant centers. These efforts are aimed at ensuring a rapid and effective market penetration.

Mesoblast Limited (NASDAQ:MESO) is also focusing on educating healthcare providers about the benefits and appropriate use of Remestemcel-L, which is expected to be a key factor in driving adoption. The company is leveraging its existing infrastructure and partnerships to facilitate a smooth rollout, with the goal of capturing a significant share of the SR-aGVHD market, which is estimated to have a substantial total addressable market (TAM).

Furthermore, Mesoblast Limited (NASDAQ:MESO) is actively expanding the therapeutic applications of Remestemcel-L. The company is currently conducting a phase 3 study in adult patients with SR-aGVHD, which is expected to commence shortly after the pediatric approval. Additionally, Remestemcel-L is being evaluated for its potential to treat inflammatory bowel disease (IBD), a condition that affects millions of people worldwide.